secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001171843-26-000154
Event type: other
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack
-----------------------------------------------------------------

- Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.
- The price increase applies to both the 150mg and 110mg capsule strengths.
- BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326000154/0001171843-26-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326000154/f8k_010826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer